Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1572-1586

  Meltzer, H Y ^a   Massey, B W ^a   Horiguchi, M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Dopamine; Glutamate; Hallucinogens; NMDA receptor; Novel object recognition; Phencyclidine; Schizophrenia; Serotonin

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 3 [2 [2 (4 METHYL 1 PIPERIDINYL)ETHYL] 1 PYRROLIDINESULFONYL]PHENOL; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; DIZOCILPINE; F 15603; FLUOXETINE; FLUPERLAPINE; HALOPERIDOL; ILOPERIDONE; KETAMINE; LURASIDONE; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PIMAVANSERIN; QUETIAPINE; RACLOPRIDE; RISPERIDONE; RITANSERIN; S 46349B; SEROTONIN 2A RECEPTOR; TENILAPINE; TIOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE; ZOTEPINE;

ARTICLE; ATTENTION; BODY WEIGHT; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DECLARATIVE MEMORY; DISEASE MODEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; EXECUTIVE FUNCTION; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; LOCOMOTION; LOW DRUG DOSE; MENTAL FUNCTION; MONOTHERAPY; MOOD DISORDER; NEGATIVE SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RECEPTOR BLOCKING; SCHIZOPHRENIA; SIDE EFFECT; SUICIDE;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; HUMANS; PSYCHOTIC DISORDERS; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS;

EID: 84862609103     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784880     Document Type: Article

References (203)

1. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H.Y. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 1988, 45, 789-796.
2. Lee, M.A.; Jayathilake, K.; Meltzer, H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schiz. Res., 1999, 37, 1-11.
3. Meltzer, H.Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J.H. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's Disease psychosis. Neuropsychopharmacology, 2010, 35(4), 881-892.
4. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol., 2003 Oct, 27(7), 1159-1172.
5. Meltzer, H.Y.; Huang, M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog. Brain. Res., 2008, 172, 177-197.
6. Gray, J.A.; Roth, B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull., 2007, 33(5), 1100-1119.
7. Kapur, S.; Seeman, P. Does fast dissociation from the dopamine Dd(2) receptor explain the action of atypical antipsychotics?: A new hypothesis Am. J. Psychiatry., 2001, 158(3), 360-369
8. Remington, G.; Kapur, S. Antipsychotic dosing: how much but also how often? Schizophr. Bull., 2010, 36(5), 900-903.
9. Seeman, P.; Battaglia, G.; Corti, C.; Corsi, M.; Bruno, V. Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2(High) receptors and marked supersensitivity to the dopamine agonist (+)PHNO. Synapse, 2009, 63(3), 247-251.
10. Fiorella, D.; Helsley, S.; Rabin, R.A.; Winter, J.C. The interactions of typical and atypical antipsychotics with the (-)2,5-dimethoxy-4- methamphetamine (DOM) discriminative stimulus. Neuropharmacol., 1995, 34, 1297-1303.
11. Silva, M.T.; Calil, H.M.; Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia, 1975, 42(2), 163-171.
12. Canal, C.E.; Olaghere da Silva, U.B.; Gresch, P.J.; Watt, E.E.; Sanders-Bush, E.; Airey, D.C.; The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl.), 2010, 2, 163-174.
13. Mita, T.; Hanada, S.; Nishino, N.; Kuno, T.; Nakai, H.; Yamadori, T.; Mizoi, Y.; Tanaka, C. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry., 1986, 21(14), 1407-1414.
14. Arora, R.C.; Meltzer, H.Y. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural. Transm. Gen. Sect., 1991, 85(1), 19-29.
15. Laruelle, M.; Abi-Dargham, A.; Casanova, M.F.; Toti, R.; Weinberger, D.R.; Kleinman, J.E. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psychiatry., 1993, 50(10), 810-818.
16. Burnet, P.W.; Eastwood, S.L.; Harrison, P.J. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology, 1996, 15(5), 442-455.
17. Dean, B.; Hayes, W.; Hill, C.; Copolov, D. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon? Mol. Chem. Neuropathol., 1998, 34(2-3),133-145.
18. Pralong, D.; Tomaskovic-Crook, E.; Opeskin, K.; Copolov, D.; Dean, B. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr. Res., 2000, 44(1), 35-45.
19. Matsumoto, I.; Inoue, Y.; Iwazaki, T.; Pavey, G.; Dean, B. 5-HT2A and muscarinic receptors in schizophrenia: a postmortem study. Neurosci. Lett., 2005, 379(3), 164-168.
20. Steward, L.J.; Kennedy, M.D.; Morris, B.J.; Pratt, J.A. The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors. Neuropharmacology, 2004 Sep, 47(4), 527-537.
21. Dean, B.; Crossland, N.; Boer, S.; Scarr, E. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. Schizophr. Res., 2008, 104(1/3), 185-197.
22. Hernandez, I.; Sokolov, B.P. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J. Neurosci. Res., 2000, 59(2), 218-225.
23. Rasmussen, H.; Ebdrup, B.H.; Erritzoe, D.; Aggernaes, B.; Oranje, B.; Kalbitzer, J.; Pinborg, L.H.; Baaré, W.F.; Svarer, C.; Lublin, H.; Knudsen, G.M.; Glenthoj, B. Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl.), 2010, 213(2/3), 583-592.
24. Hurlemann, R.; Matusch, A.; Kuhn, K.U.; Berning, J.; Elmenhorst, D.; Winz, O.; Kolsch, H.; Zilles, K.; Wagner, M.; Maier, W.; Bauer, A. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology(Berl.), 2008, 195(4), 579-590.
25. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2, and serotonin2 pKi values. J. Pharmacol. Exp. Ther., 1989, 251, 238-246.
26. Schotte, A.; Janssen, P.F.; Gommeren, W.; Luyten, W.H.; Van Gompel, P.; Lesage, A.S.; De Loore, K.; Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol., 1996, 124, 57-73.
27. Meltzer, H.Y.; Sumiyoshi, T.; Jayathilake, K. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatry Res., 2001, 105(3), 201-209.
28. Bjerkenstedt, L. Melperone in the treatment of schizophrenia. Acta. Psychiatr. Scand. Suppl., 1989, 352, 35-39.
29. Swainston Harrison, T.; Perry, C.M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs, 2004, 64(15), 1715-1736.
30. Olbrich, R.; Schanz, H. An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics. J. Neural Transm. Gen. Sect., 1991, 84(3), 233-236.
31. Duval, F.; Mokrani, M.C.; Macher, J.P.; Crocq, M.A.;, Castro J.O.; Bailey, P.; Lataste, X. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients. Psychopharmacology (Berl.), 1993, 110(1/2), 177-180.
32. Meyer, J.M.; Loebel, A.D.; Schweizer, E. Lurasidone: a new drug in development for schizophrenia. Expert Opin. Investig. Drugs, 2009, 18(11), 1715-1726.
33. Ishibashi, T.; Horisawa, T.; Tokuda, K.; Ishiyama, T.; Ogasa, M.; Tagashira, R.; Matsumoto, K.; Nishikawa, H.; Ueda, Y.; Toma, S.; Oki, H.; Tanno, N.; Saji, I.; Ito, A.; Ohno, Y.; Nakamura, M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther., 2010, 334(1), 171-181.
34. Meltzer, H.Y.; Bobo, W.V. Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr., 2006, 11(7 Suppl. 7), 14-24.
35. Kraemer, H.C.; Glick, I.D.; Klein, D.F. Clinical trials design lessons from the CATIE study. Am. J. Psychiatry, 2009, (166), 1222-1228.
36. Naber, D.; Lambert, M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs, 2009, 23(8),649-659.
37. Woodward, N.D.; Purdon, S.E.; Meltzer, H.Y.; Zald, D.H. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol., 2005, 8(3), 457-472.
38. Keefe, R.S.; Bilder, R.M.; Davis, S.M.; Harvey, P.D.; Palmer, B.W.; Gold, J.M.; Meltzer, H.Y.; Green, M.F.; Capuano, G.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Davis, C.E.; Hsiao, J.K.; Lieberman, J.A. CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry, 2007, 64(6), 633-647.
39. Jakab, R.L.; Goldman-Rakic, P.S. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci. USA, 1998, 95, 735-740.
40. Kapur, S.; Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry, 1996, 153, 466-476.
41. Kapur, S.; Zipursky, R.; Jones, C.; Shammi, C.S.; Remington, G.; Seeman, P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry, 2000, 57, 553-559.
42. Weiner, D.M.; Burstein, E.S.; Nash, N.; Croston, G.E.; Currier, E.A.; Vanover, K.E.; Harvey, S.C.; Donohue, E.; Hansen, H.C.; Andersson, C.M.; Spalding, T.A.; Gibson, D.F.; Krebs-Thomson, K.; Powell, S.B.; Geyer, M.A.; Hacksell, U.; Brann, M.R. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther., 2001, 299, 268-276.
43. Matsubara, S.; Meltzer, H.Y. Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sci., 1989, 45(15), 1397-1406.
44. Schmidt, C.J.; Sorensen, S.M.; Kehne, J.H.; Carr, A.A.; Palfreyman, M.G. The role of 5-HT2A receptors in antipsychotic activity Life Sci., 1995, 56, 2209-2222.
45. Gleason, S.D.; Shannon, H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacol., 1997, 129,79-84.
46. Martin, P.; van den Buuse, M. Phencyclidine-induced locomotor hyperactivity is enhanced in mice after stereotaxic brain serotonin depletion. Behav. Brain Res., 2008, 191(2), 289-293.
47. Varty, G.B.; Higgins, G.A. Reversal of dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur. J. Pharmacol., 1995, 287, 201-205.
48. Prinssen, E.P.; Ellenbroek, B.A.; Cools, A.R. Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol., 1994, 262, 167-170.
49. Bortolozzi, A.; Diaz-Mataix, L.; Scorza, M.C.; Celada, P.; Artigas, F. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J. Neurochem., 2005, 95, 1597-1607.
50. Coyle, J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol. Neurobiol., 2006, 26(4/6), 365-384.
51. Large, C.H. Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychopharmacol., 2007, 21(3), 283-301.
52. Lahti, A.C.; Koffel, B.; LaPorte, D.; Tamminga, C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology, 1995, 13, 9-19.
53. Malhotra, A.K.; Pinals, D.A.; Adler, C.M.; Elman, I.; Clifton, A.; Pickar, D.; Breier, A. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology, 1997b, 17, 141-150.
54. Gouzoulis-Mayfrank, E.; Heekeren, K.; Neukirch, A.; Stoll, M.; Stock, C.; Obradovic, M.; Kovar, K.A. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry, 2005, 38, 301-311.
55. Bubeníková-Valesová, V.; Horácek, J.; Vrajová, M.; Höschl, C. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci. Biobehav. Rev., 2008, 32(5), 1014-1023.
56. Corbett, R.; Camacho, F.; Woods, A.T.; Kerman, L.L.; Fishkin, R.J.; Brooks, K.; Dunn, R.W. Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology, 1995, 120(1), 67-74.
57. Maurel-Remy, S.; Bervoets, K.; Millan, M.J. Blockade of phencyclidine- induced hyperlocomotion by MDL100,907 in rats reflects antagonism of 5-HT2A receptors. Eur. J. Pharmacol., 1995, 280, R9-R11
58. Schmidt, C.J.; Fadayel, G.M. Regional effects of MK-801 on dopamine release: effects of competitive NMDA or 5-HT2A receptor blockade. J. Pharmacol. Exp. Ther., 1996, 277(3), 1541-1549.
59. Martin, P.; Waters, N.; Carlsson, A.; Carlsson, M.L. The apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural. Transm., 1997, 104(4/5), 561-564.
60. Millan, M.J.; Brocco, M.; Gobert, A.; Joly, F.; Bervoets, K.; Rivet, J.M.; Newman-Tancredi, A.; Audinot, V.; Maurel, S. Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5- HT2A site for PCP-induced locomotion in the rat. Eur. J. Neurosci., 1999, 11, 4419-4432.
61. Vanover, K.E.; Weiner, D.M.; Makhay, M.; Veinbergs, I.; Gardell, L.R.; Lameh, J.; Del Tredici, A.L.; Piu, F.; Schiffer, H.H.; Ott, T.R.; Burstein, E.S.; Uldam, A.K.; Thygesen, M.B.; Schlienger, N.; Andersson, C.M.; Son, T.Y.; Harvey, S.C.; Powell, S.B.; Geyer, M.A.; Tolf, B.R.; Brann, M.R.; Davis, R.E. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1- methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R, 3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine2A receptor inverse agonist. J. Pharmacol. Exp. Ther., 2006, 317, 910-918.
62. Gardell, L.R.; Vanover, K.E.; Pounds, L.; Johnson, R.W.; Barido, R.; Anderson G.T.; Veinbergs, I.; Dyssegaard, A.; Brunmark, P.; Tabatabaei, A.; Davis, R.E.; Brann, M.R.; Hacksell, U.; Bonhaus, D.W. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther., 2007, 322(2), 862-870.
63. Del Arco, A.; Mora, F.; Mohammed, A.H.; Fuxe, K. Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens. J. Neural. Transm., 2007, 114(2), 186-193.
64. Del Arco, A.; Mora, F. Prefrontal cortex-nucleus accumbens interaction: in vivo modulation by dopamine and glutamate in the prefrontal cortex. Pharmacol. Biochem. Behav., 2008, 90(2), 226-235.
65. Del Arco, A.; Mora, F. Neurotransmitters and prefrontal cortexlimbic system interactions: implications for plasticity and psychiatric disorders. J. Neural. Transm., 2009, 116(8), 941-952
66. Lannes, B.; Micheletti, G.; Warter, J.M.; Kempf, E.; Di Scala, G. Behavioral, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat. Neurosci. Lett., 1991, 128, 177-181.
67. Jentsch, D.J.; Taylor, J.R.; Roth, R.H. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion. Neuropsychopharmacology, 1998, 19, 105-113.
68. French, E.D.; Vantini, G. Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: comparisons to other psychomotor stimulants. Psychopharmacology., 1984, 82, 83-88.
69. French, E.D.; Pilapil, C.; Quirion, R. Phencyclidine binding sites in the nucleus accumbens and phencyclidine-induced hyperactivity are decreased following lesions of the mesolimbic dopamine system. Eur. J. Pharmacol., 1985, 116, 1-9
70. French, E.D.; Ferkany, J.; Abreu, M.; Levenson, S. Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology, 1991, 30(10), 1039-1046.
71. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 1991, 148, 1301-1308.
72. Löscher, W.; Annies, R.; Hönack, D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett., 1991, 128, 191-194.
73. Amargós-Bosch, M.; López-Gil, X.; Artigas, F.; Adell, A. Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine. Int. J. Neuropsychopharmacol., 2006, 9(5), 565-573.
74. Martin, P.; Waters, N.; Schmidt, C.J.; Carlsson, A.; Carlsson, M.L. Rodent data and general hypothesis: antipsychotic action exerted through 5-HT2A receptor antagonism is dependent on increased serotonergic tone. J. Neural. Transm., 1998, 105(4-5), 365-396.
75. Calcagno, E.; Carli, M.; Baviera, M.; Invernizzi, R.W. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J. Neurochem., 2009, 108, 521-532.
76. Snigdha, S.; Horiguchi, M.; Huang, M.; Li, Z.; Shahid, M.; Neill, J.C.; Meltzer, H.Y. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J. Pharmacol. Exp. Ther., 2010, 332(2), 622-631.
77. Gardell, L.R.; Vanover, K.E. Pounds, L.; Johnson, R.E.; Barido, R.E.; Anderson, G.T.; Veinbergs, I.; Dyssegaard, A.; Brunmark, P.; Tabatabaei, A.; Davis, R.E.; Brann, M.R.; Hacksell, U.; Bonhaus, D.W. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J. Pharmacol. Exp. Ther., 2007, 322(2), 862-870.
78. Huang, M.; Li, Z.; Prus, A.J.; Ichikawa, J.; Dai, J.; Meltzer, H.Y. 5- HT2a and 5-HT2c receptor antagonism enhances risperidone-induced dopamine (da) efflux in rat medial prefrontal cortex (mpfc) and diminishes it in the nucleus accumbens (NAC). Neurosci. Abs., 2005, 914, 10.
79. Liegeois, J-F.; Ichikawa, J.; Meltzer, H.Y. 5HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res., 2002, 947, 157-165.
80. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W.L.; O'Laughlin, I.A.; Meltzer, H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem., 2001, 76(5), 1521-1531.
81. Weisel, J.W.; Nagaswami, C.; Korsholm, B.; Petersen, L.C.; Suenson, E. Interactions of plasminogen with polymerizing fibrin and its derivatives, monitored with a photoaffinity cross-linker and electron microscopy. J. Mol. Biol., 1994, 235(3), 1117-1135.
82. Akhondzadeh, S.; Malek-Hosseini, M.; Ghoreishi, A.; Raznahan, M.; Rezazadeh, S.A. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Prog. Neuropsychopharmacol. Biol. Psychiatry., 2008, 32(8), 1879-1883.
83. Rinaldi-Carmona, M.; Congy, C.; Santucci, V.; Simiand, J.; Gautret, B.; Neliat, G.; Labeeuw, B.; Le Fur, G.; Soubrié, P.G.; Breliere, J.C. Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonists. J. Pharmacol. Exp. Ther., 1992, 262, 759-768.
84. Meltzer, H.Y.; Arvanitis, L.; Bauer, D.; Rein, W.; Meta-Trial Study Group. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 2004, 161(6), 975-984.
85. Li, Z.; Ichikawa, J.; Huang, M.; Prus, A.J.; Dai, J.; Meltzer, H.Y. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidolinduced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl.), 2005, 183(2), 144-153.
86. Meltzer, H.Y.; Mills, R.; Revell, S.; Williams, H.; Johnson, A.; Bahr, D.; Friedman, J.H. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson's Disease psychosis. Neuropsychopharmacology, 2010, 35(4), 881-892.
87. Meltzer, H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci., 1995, 3(2), 64-75.
88. Pazos, A.; Probst, A.; Palacios, J.M. Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience, 1987, 21(1), 123-139.
89. Di Giovanni, G.; Di Matteo, V.; Di Mascio, M.; Esposito, E. Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study. Synapse, 2000, 35(1), 53-61.
90. De Deurwaerdère, P.; Navailles, S.; Berg, K.A.; Clarke, W.P.; Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci., 2004, 24(13), 3235-3241.
91. Niswender, C.M.; Copeland, S.C.; Herrick-Davis, K.; Emeson, R.B.; Sanders-Bush, E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J. Biol. Chem., 1999, 274(14), 9472-9478.
92. Rula, E.Y.; Emeson, R.B. Mouse models to elucidate the functional roles of adenosine-to-inosine editing. Methods Enzymol., 2007, 424, 333-367.
93. Englander, M.T.; Dulawa, S.C.; Bhansali, P.; Schmauss, C. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J. Neurosci., 2005, 25(3), 648-651
94. Gardiner, K.; Du, Y. A-to-I editing of the 5HT2C receptor and behaviour. Brief Funct. Genomic Proteomic., 2006, 5(1), 37-42.
95. Bhansali, P.; Dunning, J.; Singer, S.E.; David, L.; Schmauss, C. Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric Gprotein G q. J. Neurosci., 2007, 27(6), 1467-1473.
96. Doe, C.M.; Relkovic S, Garfield, A.S.; Dalley, J.W.; Theobald, D.E.; Humby, T.; Wilkinson, L.S.; Isles, A.R. Loss of the imprinted snoRNA mbii-52 leads to increased 5htr2c pre-RNA editing and altered 5HT2CR-mediated behaviour. Hum. Mol. Genet., 2009, 18(12), 2140-2148.
97. Bancescu, D.L.; Glatt-Deeley, H.; Lalande, M. Epigenetic activation of the 5-hydroxytryptamine (serotonin) receptor 2C in embryonal carcinoma cells is DNA replication-dependent. Exp. Cell. Res., 2004, 298(1), 262-267.
98. Reynolds, G.P.; Templeman, L.A.; Zhang, Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progr. Neuro-Psychopharmacol. Biolog. Psychiatry, 2005, 29(6), 1021-1028.
99. Sodhi, M.S.; Airey, D.C.; Lambert, W.; Burnet, P.W.; Harrison, P.J.; Sanders-Bush, E. A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts. Mol. Pharmacol., 2005, 68(3), 711-719.
100. Chang, M.; Zhang, L.; Tam, J.P.; Sanders-Bush, E. Dissecting G protein-coupled receptor signaling pathways with membranepermeable blocking peptides. Endogenous 5-HT(2C) receptors in choroid plexus epithelial cells. J. Biol. Chem., 2000, 275(10), 7021-7029.
101. Leggio, G.M.; Cathala, A.; Neny, M.; Rouge-Pont, F.; Drago, F.; Piazza, P.V.; Spampinato, U. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. J. Neurochem., 2009, 111,614-623.
102. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens. Neuropharmacology., 1998, 37(2), 265-272.
103. Di Matteo, V.; Di Giovanni, G.; Di Mascio, M.; Esposito, E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology, 1999, 38(8), 1195-1205.
104. De Deurwaerdere, P.; Spampinato, U. Role of serotonin(2A) and serotonin(2B/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem., 1999, 73(3), 1033-1042.
105. Canal, C.E.; Olaghere da Silva, U.B.; Gresch, P.J.; Watt, E.E.; Sanders-Bush, E.; Airey, D.C. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacology (Berl.), 2010, (2),163-174.
106. Herrick-Davis, K.; Grinde, E.; Teitler, M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J. Pharmacol. Exp. Ther., 2000, 295(1), 226-232.
107. Roth, B.L.; Ciaranello, R.D.; Meltzer, H.Y. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J. Pharmacol. Exp. Ther., 1992, 260, 1361-1365.
108. Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J. Jr.; Shen, Y.; Meltzer, H.Y.; Sibley, D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5- hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther., 1994, 268(3), 1403-1410.
109. Dunlop, J.; Sabb, A.L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R.L.; Stack, G.; Schechter, L.; Harrison, B.L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta- [b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp. Ther., 2005, 313(2), 862-869.
110. Marquis, K.L.; Sabb, A.L.; Logue, S.F.; Brennan, J.A.; Piesla, M.J.; Comery, T.A.; Grauer, S.M.; Ashby, C.R. Jr.; Nguyen, H.Q.; Dawson, L.A.; Barrett, J.E.; Stack, G.; Meltzer, H.Y.; Harrison, B.L.; Rosenzweig-Lipson, S. WAY-163909 [(7bR,10aR)- 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta- [b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J. Pharmacol. Exp. Ther., 2007, 320(1), 486-496.
111. Cussac, D.; Boutet-Robinet, E.; Ailhaud, M.C.; Newman-Tancredi, A.; Martel, J.C.; Danty, N.; Rauly-Lestienne, I. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5- HT2C-VSV receptors mediated Gq/11 activation and calcium mobilization in CHO cells. Eur. J. Pharmacol., 2008, 594(1/3), 32-38.
112. Bays, H.E. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease. Expert. Rev. Cardiovasc. Ther., 2009, 7(11),1429-1445.
113. Calcagno, E.; Carli, M.; Invernizzi, R.W. The 5-HT1A receptor agonist 8-OH-DPAT prevents prefrontocortical glutamate and serotonin release in response to blockade of cortical NMDA receptors. J. Neurochem., 2006, 96, 853-860
114. Newman-Tancredi, A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: Rationale and perspectives. Curr. Opin. Investig. Drugs, 2010, 11(7), 802-812.
115. McCreary, A.C.; Jones, C.A. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr. Pharm. Des., 2010, 16(5), 516-521.
116. Wadenberg, M.L. Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural. Transm. Gen. Sect., 1992, 89, 49-59.
117. Kalkman, H.O.; Subramanian, N.; Hoyer, D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/ serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology, 2001, 25(6), 904-914.
118. Newman-Tancredi, A.; Gavaudan, S.; Conte, C.; Chaput, C.; Touzard, M.; Verrièle, L.; Audinot, V.; Millan, M.J. Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur. J. Pharmacol., 1998, 355(2/3), 245-256.
119. Ichikawa, J.; Li, Z.; Dai, J.; Meltzer, H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res., 2002, 956(2), 349-357.
120. Assié, M.B.; Ravailhe, V.; Faucillon, V.; Newman-Tancredi, A. Contrasting contribution of 5-hydroxytryptamine 1a receptor activation to neurochemical profile of novel antipsychotics: frontocor tical dopamine and hippocampal serotonin release in rat brain. J. Pharmacol. Exp. Ther., 2005, 315(1), 265-272.
121. Rollema, H.; Lu, Y.; Schmidt, A.W.; Zorn, S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur. J. Pharmacol., 1997, 338, R3-5.
122. Ichikawa, J.; Dai, J.; O'Laughlin, I.A.; Dai, J.; Fowler, W.; Meltzer, H.Y. Atypical, but not typical, antipsychotic drugs selectively increase acetylcholine release in rat medial prefrontal cortex, nucleus accumbens and striatum. Neuropsychopharmacol., 2002b, 26 (3), 325-339.
123. Chung, Y.C.; Li, Z.; Dai, J.; Meltzer, H.Y.; Ichikawa, J. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain. Res., 2004, 1023, 54-63.
124. Diaz-Mataix, L.; Scorza, M.C.; Bortolozzi, A.; Toth, M.; Celada, P.; Artigas, F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci., 2005, 25(47), 10831-10843.
125. Depoortère, R.; Auclair, A.L.; Bardin, L.; Bruins, S.L.; Kleven, M.S.; Colpaert, F.; Vacher, B.; Newman-Tancredi, A. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. Br. J. Pharmacol., 2007, 151(2), 266-277.
126. Bruins Slot, L.A.; Lestienne, F.; Grevoz-Barret, C.; Newman- Tancredi, A.; Cussac, D. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum. Eur. J. Pharmacol., 2009, 620(1/3), 27-35.
127. Harvey, P.D.; Green, M.F.; Keefe, R.S.; Velligan, D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J. Clin. Psychiatry, 2004, 65(3), 361-372.
128. Meltzer, H.Y.; McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull., 1999, 25, 233-255.
129. Hagger, C.; Buckley, P.; Kenny, J.T.; Friedman, L.; Ubogy, D.; Meltzer, H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry., 1993, 34, 702-712.
130. Newcomer, J.W.; Farber, N.B.; Jevtovic-Todorovic, V.; Selke, G.; Melson, A.K.; Hershey, T.; Craft, S.; Olney, J.W. Ketamineinduced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology, 1999, 20(2), 106-118.
131. Saykin, A.J.; Gur, R.C.; Gur, R.E.; Mozley, P.D.; Mozley, L.H.; Resnick, S.M.; Kester, D.B.; Stafiniak, P. Neuropsychological function in schizophrenia: Selective impairment in memory and learning. Arch. Gen. Psychiatry., 1991, 48(7), 618-624.
132. Meltzer, H.Y.; McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull., 1999, 25, 233-255.
133. Winters, B.D.; Saksida, L.M.; Bussey, T.J. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci. Biobehav. Rev., 2008, 32(5), 1055-1070.
134. Winters, B.D.; Saksida, L.M.; Bussey, T.J. Implications of animal object memory research for human amnesia. Neuropsychologia, 2010, 48, 2251-2261
135. Clark, R.E.; Squire, L.R. An animal model of recognition memory and medial temporal lobe amnesia: History and current issues. Neuropsychologia, 2010, 48, 2234-2244.
136. Young, J.W.; Powell, S.; Risbrough, V.; Marston, H.M.; Geyer, M.A. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther., 2009, 122(2), 150-202.
137. Dere, E.; Huston, J.P.; De Souza Silva, M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci. Biobehav. Rev., 2007, 31(5), 673-704.
138. Grayson, B.I.; Idris, N.F.; Neill, J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav. Brain Res., 2007, 184(1), 31-38.
139. Hashimoto, K.; Fujita, Y.; Shimizu, E.; Iyo, M. Phencyclidineinduced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol., 2005, 519, 114-117.
140. Nagai, T.; Murai, R.; Matsui, K.; Kamei, H.; Noda, Y.; Furukawa, H.; Nabeshima, T. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology, 2009, 202(1/3), 315-328.
141. Hagiwara, H.; Fujita, Y.; Ishima, T.; Kunitachi, S.; Shirayama, Y.; Iyo, M.; Hashimoto, K. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors. Eur. Neuropsychopharmacol., 2008, 18(6), 448-454.
142. McKibben, C.E.; Jenkins, T.A.; Adams, H.N.; Harte, M.K.; Reynolds, G.P. Effect of pretreatment with risperidone on phencyclidine- induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat. Behav. Brain Res., 2010, 208(1), 132-136.
143. Wagner, M.; Quednow, B.B.; Westheide, J.; Schlaepfer, T.E.; Maier, W.; Kühn, K.U. Cognitive improvement in schizophrenic patients does notrequire a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacol., 2005, 30, 381-390.
144. Kuroki, T.; Meltzer, H.Y.; Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther., 1999, 288(2), 774-781.
145. Bonaccorso, S.; Meltzer, H.Y.; Li, Z.; Dai, J.; Alboszta, A.R.; Ichikawa, J. SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacol., 2002, 27, 430-441,
146. Parada, M.A.; Hernandez, L.; Puig de Parada, M.; Rada, P.; Murzi, E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther., 1997, 281, 582-588.
147. Ichikawa, J.; Li, Z.; Dai, J.; Meltzer, H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res., 2002a, 956(2), 349-357.
148. Shirazi-Southall, S.; Rodriguez, D.E.; Nomikos, G.G. Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacol., 2002, 26(5), 583-594.
149. Tanibuchi, Y.; Fujita, Y.; Kohno, M.; Ishima, T.; Takatsu, Y.; Iyo, M.; Hashimoto, K. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of alpha1-adrenoceptors. Eur. Neuropsychopharmacol., 2009, 19(12), 861-867.
150. Idris, N.; Neill, J.; Grayson, B.; Bang-Andersen, B.; Witten, L.M.; Brennum, L.T.; Arnt, J. Sertindole improves sub-chronic PCPinduced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology, 2010, 208(1), 23-36.
151. Karasawa, J.; Hashimoto, K.; Chaki, S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res., 2008, 186(1), 78-83.
152. Horiguchi, M.; Huang, M.; Meltzer, H.Y: Interaction of mGluR 2/3 agonism with clozapine and lurasidone to restore novel object recognition in phencyclidine-treated rats. Psychopharmacology, 2011, 217(1), 13-24.
153. Kehne, J.H.; Baron, B.M.; Carr, A.A.; Chaney, S.F.; Elands, J.; Feldman, D.J.; Frank, R.A.; van Giersbergen, P.L.; McCloskey, T.C.; Johnson, M.P.; McCarty, D.R.; Poirot, M.; Senyah, Y.; Siegel, B.W.; Widmaier, C: Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther., 1996, 277(2), 968-981.
154. Wang, R.Y.; Liang, X: M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology, 1995, 19(1), 74-85.
155. Horiguchi, M.; Meltzer, H.Y: 5-HT7 receptor antagonism contributes to the ability of atypical antipsychotic drugs, including lurasidone and amisulpride, to reverse the phencyclidine (PCP)-induced deficit in novel object recognition in rats. Abs. Am. College Neuropsychopharmacol., 2010, 338(2),605-614
156. Gozzi, A.; Crestan, V.; Turrini, G.; Clemens, M.; Bifone, A. Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit. Psychopharmacology (Berl.), 2010, 209(1), 37-50.
157. Yuen, E.Y.; Jiang, Q.; Chen, P.; Gu, Z.; Feng, J.; Yan, Z: Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule- dependent mechanism. J. Neurosci., 2005, 25(23), 5488-5501.
158. González-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V; López-Giménez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C: Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452(7183), 93-97.
159. Gewirtz, J.C.; Marek, G.J: Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology, 2000, 23(5), 569-576.
160. Marek, G.J.; Wright, R.A.; Schoepp, D.D.; Monn, J.A.; Aghajanian, G.K: Physiological antagonism between 5- hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther., 2000, 292(1), 76-87.
161. Cartmell, J.; Monn, J.A.; Schoepp, D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther., 1999, 291(1), 161-170.
162. Swanson, C.J.; Schoepp, D.D: The group II metabotropic glutamate receptor agonist (-)-2-oxa-4-aminobicyclo[3.1.0]-hexane-4,6-dicarboxylate (LY379268) and clozapine reverse phencyclidineinduced behaviors in monoamine-depleted rats. J. Pharmacol. Exp. Ther., 2002, 303, 919-927.
163. Hoyer, D.; Pazos, A.; Probst, A.; Palacios, J.M: Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res., 1986, 376(1), 85-96.
164. Meneses, A.; Perez-Garcia G: 5-HT(1A) receptors and memory. Neurosci. Biobehav. Rev., 2007, 31(5), 705-727.
165. Ogren, S.O.; Eriksson, T.M.; Elvander-Tottie, E.; D'Addario, C.; Ekström, J.C.; Svenningsson, P.; Meister, B.; Kehr, J.; Stiedl, O: The role of 5-HT(1A) receptors in learning and memory. Behav. Brain Res., 2008, 195(1), 54-77.
166. Bantick, R.A.; Deakin, J.F.; Grasby, P.M: The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J. Psychopharmacol., 2001, 15(1), 37-46.
167. Goldman-Rakic, P.S.; Selemon, L.D: Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull., 1997, 23(3), 437-458.
168. Yuen, E.Y.; Jiang, Q.; Chen, P.; Feng, J.; Yan, Z: Activation of 5- HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-Daspartate receptor channels in pyramidal neurons of prefrontal cortex. J. Biol. Chem., 2008, 283(25), 17194-17204.
169. Sumiyoshi, T.; Matsui, M.; Yamashita, I.; Nohara, S.; Uehara, T.; Kurachi, M.; Meltzer, H.Y: Effect of adjunctive treatment with serotonin- 1A agonist tandospirone on memory functions in schizophrenia. J. Clin. Psychopharmacol., 2000, 20(3), 386-388.
170. Sumiyoshi, T.; Matsui, M.; Nohara, S.; Yamashita, I.; Kurachi, M.; Sumiyoshi, C.; Jayathilake, K.; Meltzer, H.Y: Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry, 2001a, 158(10), 1722-1725.
171. Sumiyoshi, T.; Matsui, M.; Yamashita, I.; Nohara, S.; Kurachi, M.; Uehara, T.; Sumiyoshi, S.; Sumiyoshi, C.; Meltzer, H.Y: The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia. Biol. Psychiatry, 2001b, 49(10), 861-868.
172. Tanaka, H.; Tatsuno, T.; Shimizu, H.; Hirose, A.; Kumasaka, Y.; Nakamura, M: Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain. Gen. Pharmacol., 1995, 26(8), 1765-1772.
173. Choi, Y.K.; Snigdha, S.; Shahid, M.; Neill, J.C.; Tarazi, F.I: Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J. Mol. Neurosci., 2009, 38(3), 227-235.
174. Boast, C.; Bartolomeo, A.C.; Morris, H.; Moyer, J.A: 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. Neurobiol. Learn Mem., 1999, 71(3), 259-271.
175. Pitsikas, N.; Rigamonti, A.E.; Cella, S.G.; Muller, E.E: The 5-HT 1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task. Brain Res., 2003, 983(1/2), 215-222.
176. Hirst, W.D.; Andree, T.H.; Aschmies, S.; Childers, W.E.; Comery, T.A.; Dawson, L.A.; Day, M.; Feingold, I.B.; Grauer, S.M.; Harrison, B.L.; Hughes, Z.A.; Kao, J.; Kelly, M.G.; van der Lee, H.; Rosenzweig-Lipson, S.; Saab, A.L.; Smith, D.L.; Sullivan, K.; Rizzo, S.J.; Tio, C.; Zhang, M.Y.; Schechter, L.E: Correlating efficacy in rodent cognition models with in vivo 5- hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405). J. Pharmacol. Exp. Ther., 2008, 325(1), 134-145.
177. Di Matteo, V.; de Blasi, A.; Di Giulio, C.; Esposito, E: Role of 5- HT(2C) receptors in the control of central dopamine function. Trends Pharmacol. Sci., 2001, 22(5), 229-232.
178. Dunlop, J.; Sabb, A.L.; Mazandarani, H.; Zhang, J.; Kalgaonker, S.; Shukhina, E.; Sukoff, S.; Vogel, R.L.; Stack, G.; Schechter, L.; Harrison, B.L.; Rosenzweig-Lipson, S: WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmacol. Exp. Ther., 2005, 313(2), 862-869.
179. Grauer, S.M.; Graf, R.; Navarra, R.; Sung, A.; Logue, S.F.; Stack, G.; Huselton, C.; Liu, Z.; Comery, T.A.; Marquis, K.L.; Rosenzweig-Lipson, S: WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology, 2009, 204(1), 37-48.
180. Pitsikas, N.; Sakellaridis, N: The 5-HT2C receptor antagonist RO 60-0491 counteracts rats' retention deficits in a recognition memory task. Brain Res., 2005, 1054(2), 200-202.
181. Siuciak, J.A.; Chapin, D.S.; McCarthy, S.A.; Guanowsky, V.; Brown, J.; Chiang, P.; Marala, R.; Patterson, T.; Seymour, P.A.; Swick, A.; Iredale, P.A: CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity. Neuropharmacology, 2007, 52(2), 279-290.
182. Bromidge, S.M.; Davies, S.; Duckworth, D.M.; Forbes, I.T.; Jones, G.E.; Jones, J.; King, F.D.; Blackburn, T.P.; Holland, V.; Kennett, G.A.; Lightowler, S.; Middlemiss, D.N.; Riley, G.J.; Trail, B.; Wood, M.D: 1-[2-[(Heteroarylmethoxy)aryl]carbamoyl]indolines are selective and orally active 5-HT2C receptor inverse agonists. Bioorg. Med. Chem. Lett., 2000, 10(16), 1867-1870.
183. McLean, S.L.; Idris, N.F.; Woolley, M.L.; Neill, J.C: D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. Eur. Neuropsychopharmacol., 2009, 19(6), 440-450.
184. Meneses, A: Involvement of 5-HT(2A/2B/2C) receptors on memory formation: simple agonism, antagonism, or inverse agonism? Cell. Mol. Neurobiol., 2002, 22(5/6), 675-688.
185. Lacivita, E.; Leopoldo, M: Selective agents for serotonin2C (5- HT2C) receptors. Curr. Top. Med. Chem., 2006, 6, 1927-1970.
186. Ward, R.P.; Hamblin, M.W.; Lachowicz, J.E.; Hoffman, B.J.; Sibley, D.R.; Dorsa, D.M: Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience, 1995, 64(4), 1105-1111.
187. Monsma, F.J. Jr.; Shen, Y.; Ward, R.P.; Hamblin, M.W.; Sibley, D.R: Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol., 1993, 43(3), 320-327.
188. Kohen, R.; Metcalf, M.A.; Khan, N.; Druck, T.; Huebner, K.; Lachowicz, J.E.; Meltzer, H.Y.; Sibley, D.R.; Roth, B.L.; Hamblin, M.W: Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem., 1996, 66(1), 47-56.
189. Arnt, J.; Skarsfeldt, T: Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology, 1998, 18, 63-101.
190. Boess, F.G.; Monsma, F.J. Jr.; Sleight, A.J: Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J. Neurochem., 1998, 71(5), 2169-2177.
191. Pitsikas, N.; Zisopoulou, S.; Pappas, I.; Sakellaridis, N: The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. Behav.Brain Res., 2008, 188(2), 304-309
192. Hedlund, P.B: The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology, 2009, 206(3), 345-354.
193. Plassat, J.L.; Amlaiky, N.; Hen, R: Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol. Pharmacol., 1993, 44(2), 229-236.
194. Martín-Cora, F.J.; Pazos, A: Autoradiographic distribution of 5- HT7 receptors in the human brain using [3H]mesulergine: comparison to other mammalian species. Br. J. Pharmacol., 2004, 141(1), 92-104.
195. Hedlund, P.B.; Sutcliffe, J.G: Functional, molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci., 2004, 25(9), 481-486.
196. Thomas, D.R.; Hagan, J.J: 5-HT7 receptors. Curr. Drug Targets CNS Neurol. Disord., 2004, 3(1), 81-90.
197. Galici, R.; Boggs, J.D.; Miller, K.L.; Bonaventure, P.; Atack, J.R: Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity. Behav. Pharmacol., 2008, 19(2), 153-159.
198. Semenova, S.; Geyer, M.A.; Sutcliffe, J.G.; Markou, A.; Hedlund, P.B: Inactivation of the 5-HT(7) receptor partially blocks phencyclidine- induced disruption of prepulse inhibition. Biol. Psychiatry, 63(1), 98-105.
199. Pouzet, B.; Didriksen, M.; Arnt, J: Effects of the 5-HT(7) receptor antagonist SB-258741 in animal models for schizophrenia. Pharmacol. Biochem. Behav., 2002, 71(4), 655-665.
200. Abbas, A.I.; Hedlund, P.B.; Huang, X.P.; Tran, T.B.; Meltzer, H.Y.; Roth, B.L: Amisulpride is a potent 5-HT7 antagonist: re8levance for antidepressant actions in vivo. Psychopharmacology, 2009, 205(1), 119-128.
201. Meneses, A. Effects of the 5-HT7 receptor antagonists SB-269970 and DR 4004 in autoshaping Pavlovian/instrumental learning task. Behav. Brain Res., 2004, 155(2), 275-282.
202. McLean, S.L.; Woolley, M.L.; Thomas, D.; Neill, J.C: Role of 5- HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology, 2009b, 206(3), 403-414.
203. Meltzer, H.Y.; Horiguchi, M.; Massey, B.W: The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology (Berl.), 2011, 213(2/3), 289-305.